Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 13Recruiting 6Unknown 2Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 27Breast 26Genitourinary 18Gastrointestinal 11Thoracic 8Sarcoma 5CNS 5Head & Neck 4Tumor-Agnostic 2Other solid neoplasm 2Myeloid 2Other hematologic neoplasm 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Neoplasm Metastasis 2

Interventions

pembrolizumab 17Specimen Handling 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Paclitaxel 7Biopsy 7Nivolumab 6atezolizumab 5Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Practice Guidelines as Topic 4Pemetrexed 4Oxaliplatin 4Cyclophosphamide 4Carboplatin 4osimertinib 3niraparib 3durvalumab 3cemiplimab 3avelumab 3Radiotherapy 3Radiation 3Leucovorin 3Irinotecan 3Ipilimumab 3Interviews as Topic 3Fluorouracil 3trastuzumab deruxtecan 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × olaparib × Tumor-Agnostic × Clear all
NCT03842228 2026-05-29

COD

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04197713 2026-04-29

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

National Cancer Institute (NCI)

Phase 1 Active not recruiting
13 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡